Stephan Linden1, Regina Bussing2, Paul Kubilis3, Tobias Gerhard4, Richard Segal3, Jonathan J Shuster5, Almut G Winterstein6. 1. Pharmaceutical Outcomes and Policy, College of Pharmacy, slinden@ufl.edu. 2. Departments of Psychiatry and Pediatrics, College of Medicine, Clinical and Health Psychology, College of Public Health and Health Professions. 3. Pharmaceutical Outcomes and Policy, College of Pharmacy. 4. Ernest Mario School of Pharmacy and Institute for Health, Health Care Policy, and Aging Research, Rutgers University, New Brunswick, New Jersey. 5. Health Outcomes and Policy, UF Clinical Research Center, College of Medicine, and. 6. Pharmaceutical Outcomes and Policy, College of Pharmacy, Epidemiology, College of Public Health and Health Professions and College of Medicine. University of Florida, Gainesville, Florida; and.
Abstract
BACKGROUND: Antidepressant effects on increased suicidality in children have raised public concern in recent years. Approved in 2002 for attention-deficit/hyperactivity disorder treatment, the selective noradrenalin-reuptake-inhibitor atomoxetine was initially investigated for the treatment of depression. In post-hoc analyses of clinical trial data, atomoxetine has been associated with an increased risk of suicidal ideation in children and adolescents. We analyzed whether the observed increased risk of suicidal ideation in clinical trials translates into an increased risk of suicidal events in pediatric patients treated with atomoxetine compared with stimulants in 26 Medicaid programs. METHODS: Employing a retrospective cohort design, we used propensity score-adjusted Cox proportional hazard models to evaluate the risk of suicide and suicide attempt in pediatric patients initiating treatment with atomoxetine compared with stimulants from 2002 to 2006. RESULTS: The first-line treatment cohort included 279 315 patients. During the first year of follow-up, the adjusted hazard ratio for current atomoxetine use compared with current stimulant use was 0.95 (95% CI 0.47-1.92, P = .88). The second-line treatment cohort included 220 215 patients. During the first year of follow-up, the adjusted hazard ratio for current atomoxetine use compared with current stimulant use was 0.71 (95% CI 0.30-1.67, P = .43). CONCLUSIONS: First- and second-line treatment of youths age 5 to 18 with atomoxetine compared with stimulants was not significantly associated with an increased risk of suicidal events. The low incidence of suicide and suicide attempt resulted in wide confidence intervals and did not allow stratified analysis of high-risk groups or assessment of suicidal risk associated with long-term use of atomoxetine.
BACKGROUND: Antidepressant effects on increased suicidality in children have raised public concern in recent years. Approved in 2002 for attention-deficit/hyperactivity disorder treatment, the selective noradrenalin-reuptake-inhibitor atomoxetine was initially investigated for the treatment of depression. In post-hoc analyses of clinical trial data, atomoxetine has been associated with an increased risk of suicidal ideation in children and adolescents. We analyzed whether the observed increased risk of suicidal ideation in clinical trials translates into an increased risk of suicidal events in pediatric patients treated with atomoxetine compared with stimulants in 26 Medicaid programs. METHODS: Employing a retrospective cohort design, we used propensity score-adjusted Cox proportional hazard models to evaluate the risk of suicide and suicide attempt in pediatric patients initiating treatment with atomoxetine compared with stimulants from 2002 to 2006. RESULTS: The first-line treatment cohort included 279 315 patients. During the first year of follow-up, the adjusted hazard ratio for current atomoxetine use compared with current stimulant use was 0.95 (95% CI 0.47-1.92, P = .88). The second-line treatment cohort included 220 215 patients. During the first year of follow-up, the adjusted hazard ratio for current atomoxetine use compared with current stimulant use was 0.71 (95% CI 0.30-1.67, P = .43). CONCLUSIONS: First- and second-line treatment of youths age 5 to 18 with atomoxetine compared with stimulants was not significantly associated with an increased risk of suicidal events. The low incidence of suicide and suicide attempt resulted in wide confidence intervals and did not allow stratified analysis of high-risk groups or assessment of suicidal risk associated with long-term use of atomoxetine.
Authors: Mark Wolraich; Lawrence Brown; Ronald T Brown; George DuPaul; Marian Earls; Heidi M Feldman; Theodore G Ganiats; Beth Kaplanek; Bruce Meyer; James Perrin; Karen Pierce; Michael Reiff; Martin T Stein; Susanna Visser Journal: Pediatrics Date: 2011-10-16 Impact factor: 7.124
Authors: Mark E Bangs; Sitra Tauscher-Wisniewski; John Polzer; Shuyu Zhang; Nayan Acharya; Durisala Desaiah; Paula T Trzepacz; Albert J Allen Journal: J Am Acad Child Adolesc Psychiatry Date: 2008-02 Impact factor: 8.829
Authors: Zheng Chang; Patrick D Quinn; Lauren O'Reilly; Arvid Sjölander; Kwan Hur; Robert Gibbons; Henrik Larsson; Brian M D'Onofrio Journal: Biol Psychiatry Date: 2019-12-13 Impact factor: 13.382
Authors: Zheng Chang; Laura Ghirardi; Patrick D Quinn; Philip Asherson; Brian M D'Onofrio; Henrik Larsson Journal: Biol Psychiatry Date: 2019-04-17 Impact factor: 13.382
Authors: Louise Öhlund; Michael Ott; Robert Lundqvist; Mikael Sandlund; Ellinor Salander Renberg; Ursula Werneke Journal: Ther Adv Psychopharmacol Date: 2020-08-06
Authors: Ferrán Catalá-López; Brian Hutton; Amparo Núñez-Beltrán; Matthew J Page; Manuel Ridao; Diego Macías Saint-Gerons; Miguel A Catalá; Rafael Tabarés-Seisdedos; David Moher Journal: PLoS One Date: 2017-07-12 Impact factor: 3.240
Authors: I Conejero; I Jaussent; R Lopez; S Guillaume; E Olié; C Hebbache; R F Cohen; J P Kahn; M Leboyer; P Courtet; J Lopez-Castroman Journal: Sci Rep Date: 2019-03-14 Impact factor: 4.379
Authors: Elise M Hawkins; William Coryell; Stephen Leung; Sagar V Parikh; Cody Weston; Paul Nestadt; John I Nurnberger; Adam Kaplin; Anupama Kumar; Ali A Farooqui; Rif S El-Mallakh Journal: Brain Behav Date: 2021-10-17 Impact factor: 2.708